# A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors

> **NCT07698587** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Suzhou Biomissile Pharmaceuticals Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** BM230 & PD-1 inhibitor
- **DRUG:** BM230 & PD-1 inhibitor

## Key facts

- **NCT ID:** NCT07698587
- **Lead sponsor:** Suzhou Biomissile Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698587, "A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*